References
- Abbayya K, Puthanakar NY, Naduwinmani S, Chidambar YS. Association
between Periodontitis and Alzheimer’s Disease. N Am J Med Sci. 2015
Jun;7(6):241-6.
- Demmer RT, Holtfreter B, Desvarieux M, Jacobs DR Jr, Kerner W, Nauck
M, Völzke H, Kocher T. The influence of type 1 and type 2 diabetes on
periodontal disease progression: prospective results from the Study of
Health in Pomerania (SHIP). Diabetes Care 2012: 35:
2036–2042.
- Eke PI, Wei L, Borgnakke WS, Thornton-Evans G, Zhang X, Lu H, McGuire
LC, Genco RJ. Periodontitis prevalence in adults ≥ 65 years of age, in
the USA. Periodontol 2000. 2016 Oct;72(1):76-95.
- Kassebaum NJ, Bernabe E, Dahiya M, Bhandari B, Murray CJL, Marcenes
W. Global burden of severe periodontitis in 1990–2010: a systematic
review and meta-regression. J Dent Res 2014: 93: 1045–1053.
- Robert A Whittington, Emmanuel Planel, Niccolo Terrando. Impaired
Resolution of Inflammation in Alzheimer’s Disease: A Review. Front.
Immunol. 2017; 8:2017.
- Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting
the global burden of Alzheimer’s disease. Alzheimers
Dement (2007) 3:186–91.
- Luo H, Pan W, Sloan F, Feinglos M, Wu B. Forty-year trends in tooth
loss among American adults with and without diabetes mellitus: an
age-period-cohort analysis. Prev Chronic Dis 2015: 12: E211.
- Ma KS, Hasturk H, Carreras I, Dedeoglu A, Veeravalli JJ, Huang JY, et
al. Dementia and the risk of periodontitis: a population-based cohort
study. J Dent Res. 2022;101(3):270–7.
- Ryder, M.I. The Link Between Periodontitis and Alzheimer’s Disease:
Reality or Yet Another Association. Curr Oral Health
Rep 9 , 157–166 (2022).
- Leblhuber, F., Huemer, J., Steiner, K. et al. Knock-on effect
of periodontitis to the pathogenesis of Alzheimer’s
disease?. Wien Klin Wochenschr 132 , 493–498 (2020).
- Wang, R.PH., Huang, J., Chan, K.W.Y. et al. IL-1β and TNF-α
play an important role in modulating the risk of periodontitis and
Alzheimer’s disease. J Neuroinflammation 20 , 71
(2023).
- Azizi G, Mirshafiey A. The potential role of proinflammatory and
antiinflammatory cytokines in Alzheimer disease
pathogenesis. ImmunopharmacolImmunotoxicol. 2012; 34:881–95.
- Azizi G, Navabi SS, Al-Shukaili A, Seyedzadeh MH, Yazdani R,
Mirshafiey A. The Role of Inflammatory Mediators in the Pathogenesis
of Alzheimer’s Disease. Sultan Qaboos Univ Med J. 2015 Aug;15(3):
e305-16.
- Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation
affect chronic neurodegeneration. Nat Rev Immunol. 2007;7:161–7.
- Varatharaj A, Galea I. The blood-brain barrier in systemic
inflammation. Brain Behav Immun. 2017; 60:1–12.
- Gorlovoy P, Larionov S, Pham TT, Neumann H. Accumulation of tau
induced in neurites by microglial proinflammatory mediators. FASEB
J. 2009;23:2502–13
- Gorlovoy P, Larionov S, Pham TT, Neumann H. Accumulation of tau
induced in neurites by microglial proinflammatory mediators. FASEB
J. 2009;23:2502–13
- Lin X, Bai G, Lin L, Wu H, Cai J, Ugen KE, et al. Vaccination-induced
changes in pro-inflammatory cytokine levels as an early putative
biomarker for cognitive improvement in a transgenic mouse model for
Alzheimer’s disease. Hum VaccinImmunother. 2014;10:2024–31.
- Koyama A, O’Brien J, Weuve J, Blacker D, Metti AL, Yaffe K. The role
of peripheral inflammatory markers in dementia and Alzheimer’s
disease: a meta-analysis. J Gerontol A Biol Sci Med Sci.
2013;68(4):433–40.
- Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH.
Systemic infection, interleukin 1β, and cognitive decline in
Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2003;74(6):788–9.
- Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, et al.
Systemic inflammation and disease progression in Alzheimer disease.
Neurology. 2009;73(10):768.
- Detrait ER, Danis B, Lamberty Y, Foerch P. Peripheral administration
of an anti-TNF-α receptor fusion protein counteracts the amyloid
induced elevation of hippocampal TNF-α levels and memory deficits in
mice. Neurochem Int. 2014;72(1):10–3.
- Paul Oindrila, Arora Payal, Mayer Michael, Chatterjee Shampa.
Inflammation in Periodontal Disease: Possible Link to Vascular
Disease.Frontiers in Physiology 2021;11:2020.
- Graves DT, Cochran D. The contribution of interleukin-1 and tumor
necrosis factor to periodontal tissue destruction. J Periodontol. 2003
Mar;74(3):391-401.
- Nikolopoulos GK, Dimou NL, Hamodrakas SJ, Bagos PG. Cytokine gene
polymorphisms in periodontal disease: a meta-analysis of 53 studies
including 4178 cases and 4590 controls. J Clin Periodontol. 2008
Sep;35(9):754-67.
- Preshaw PM, Taylor JJ. How has research into cytokine interactions and
their role in driving immune responses impacted our understanding of
periodontitis? J Clin Periodontol. 2011;38:60–84.
- Park KM, Bowers WJ. Tumor necrosis factor-alpha mediated signaling in
neuronal homeostasis and dysfunction. Cell
Signal. 2010;22:977–83.
- Montgomery SL, Bowers WJ. Tumor necrosis factor-alpha and the roles it
plays in homeostatic and degenerative processes within the central
nervous system. J Neuroimmune Pharmacol. 2012;7:42–59.
- Lee KS, Chung JH, Choi TK, Suh SY, Oh BH, Hong CH. Peripheral
cytokines and chemokines in Alzheimer’s disease. Dement Geriatr
Cogn Disord. 2009;28:281–7.
- Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual
anti-inflammatory and pro-resolution lipid mediators. Nature reviews
Immunology. 2008;8(5):349–361
- Kourtzelis I, Mitroulis I, von Renesse J, Hajishengallis G, Chavakis
T. From leukocyte recruitment to resolution of inflammation: the
cardinal role of integrins. Journal of leukocyte biology.
2017;102:677–683.
- Ortega-Gomez A, Perretti M, Soehnlein O. Resolution of inflammation:
an integrated view. EMBO molecular medicine. 2013;5(5):661–674.
- Serhan CN. Pro-resolving lipid mediators are leads for resolution
physiology. Nature. 2014;510(7503):92–101.
- Serhan CN, Chiang N. Resolution phase lipid mediators of in‐
flammation: agonists of resolution. Curr Opin Pharmacol.
2013;13(4):632‐640.
- Perretti M, Leroy X, Bland EJ, Montero‐Melendez T. Resolution
pharmacology: opportunities for therapeutic innovation in inflam‐
mation. Trends Pharmacol Sci. 2015;36(11):737‐755.
- Serhan CN, Chiang N, Dalli J. New pro‐resolving n‐3 mediators bridge
resolution of infectious inflammation to tissue regeneration. Mol
Aspects Med. 2018;64:1‐17.
- m DS. Omega-3 fatty acids in anti-inflammation (pro-resolution) and
GPCRs. Prog Lipid Res 2012; 51: 232-7.
- Ryan A, Godson C. Lipoxins: regulators of resolution. Curr Opin
Pharmacol 2010; 10: 166-72.
- Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, Serhan
CN, Murphy PM. International union of basic and clinical pharmacology.
LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.
Pharmacol Rev 2009; 61: 119-61.
- Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R,
Petasis NA, Serhan CN. Resolvin D1 binds human phagocytes with
evidence for proresolving receptors. Proc Natl Acad Sci U S A 2010;
107: 1660-5.
- Serhan CN, Petasis NA. Resolvins and protectins in inflammation
resolution. Chem Rev 2011; 111: 5922-43.
- Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1
activate inflammation-resolution programmes. Nature 2007; 447: 869-74.
- Hong S, Lu Y. Omega-3 fatty acid-derived resolvins and protectins in
inflammation resolution and leukocyte functions: targeting novel lipid
mediator pathways in mitigation of acute kidney injury. Front Immunol
2013; 4: 13.
- Medeiros R, Kitazawa M, Passos GF, Baglietto-Vargas D, Cheng D, Cribbs
DH, et al. Aspirin-triggered lipoxin A4 stimulates alternative
activation of microglia and reduces Alzheimer disease-like pathology
in mice. Am J Pathol (2013) 182:1780–9.
- Dunn HC, Ager RR, Baglietto-Vargas D, Cheng D, Kitazawa M, Cribbs DH,
et al. Restoration of lipoxin A4 signaling reduces Alzheimer’s
disease-like pathology in the 3xTg-AD mouse model. J Alzheimers Dis
(2015) 43:893–903.
- Takano T, Fiore S, Maddox JF, Brady HR, Petasis NA, Serhan CN.
Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues
are potent inhibitors of acute inflammation: evidence for
anti-inflammatory receptors. J Exp Med (1997) 185:1693–704
- Torres M, Price SL, Fiol-Deroque MA, Marcilla-Etxenike A, Ahyayauch H,
Barcelo-Coblijn G, et al. Membrane lipid modifications and
therapeutic effects mediated by hydroxydocosahexaenoic acid on
Alzheimer’s disease. Biochim Biophys Acta (2014) 1838:1680–92.
- Teng E, Taylor K, Bilousova T, Weiland D, Pham T, Zuo X, et al.
Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD
reduces behavioral and Abeta pathology and modulates Abeta
oligomerization. Neurobiol Dis (2015) 82:552–60.
- Hosono T, Mouri A, Nishitsuji K, Jung CG, Kontani M, Tokuda H, et al.
Arachidonic or docosahexaenoic acid diet prevents memory impairment in
Tg2576 mice. J Alzheimers Dis (2015) 48:149–62.
- Darveau, R. P. (2010). Periodontitis: a polymicrobial disruption of
host homeostasis. Nat. Rev. Microbiol. 8, 481–490
- Michlewska, S., Dransfield, I., Megson, I. L., and Rossi, A. G.
(2009). Macrophage phagocytosis of apoptotic neutrophils is critically
regulated by the opposing actions of pro-inflammatory and
anti-inflammatory agents: key role for TNF-alpha. FASEB J. 23,
844–854.
- Cochrane (2008). New cochrane systematic reviews — cochrane oral
health group. J. Evid. Based Dent. Pract. 8, 258–260.
- Maria Balta, Bruno G. Loos, Elena A. Nicu. Emerging Concepts in the
Resolution of Periodontal Inflammation: A Role for Resolvin E1. Front.
Immunol.2017,8:1682.